Actinium Pharmaceuticals (NYSE:ATNM) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a sell rating to a hold rating in a research report released on Thursday.

A number of other equities analysts have also recently weighed in on ATNM. Maxim Group decreased their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating for the company in a report on Tuesday, August 6th. B. Riley lowered Actinium Pharmaceuticals from a buy rating to a neutral rating and dropped their target price for the stock from $16.00 to $2.00 in a research report on Wednesday, August 7th. HC Wainwright decreased their price target on Actinium Pharmaceuticals from $50.00 to $4.00 and set a buy rating for the company in a research note on Tuesday, August 6th. Finally, Stephens started coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They issued an overweight rating and a $25.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $11.43.

Actinium Pharmaceuticals Stock Up 4.2 %

Shares of NYSE ATNM opened at $1.99 on Thursday. The stock has a market cap of $59.27 million, a price-to-earnings ratio of -1.16 and a beta of 0.20. Actinium Pharmaceuticals has a one year low of $1.33 and a one year high of $10.24. The stock’s fifty day moving average is $4.62.

Actinium Pharmaceuticals (NYSE:ATNM) last announced its earnings results on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. As a group, equities research analysts forecast that Actinium Pharmaceuticals will post -1.47 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ATNM. Rhumbline Advisers lifted its holdings in shares of Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after purchasing an additional 7,525 shares during the last quarter. Sanders Morris Harris LLC purchased a new stake in shares of Actinium Pharmaceuticals during the first quarter valued at $78,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at $92,000. Bank of New York Mellon Corp lifted its holdings in shares of Actinium Pharmaceuticals by 28.3% during the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after purchasing an additional 19,035 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at $142,000. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.